<DOC>
	<DOC>NCT01441401</DOC>
	<brief_summary>This investigation aims to understand the following issues in pediatric patients, as well as to assess the need of a special investigation and a post-marketing clinical study: - The frequency of treatment related adverse events. - The frequency of efficacy assessment. - Treatment related unlisted adverse events in Japanese Package Insert. - Risk factors likely to affect the frequency of treatment related adverse event.</brief_summary>
	<brief_title>Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first gabapentin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>All the pediatric subjects (aged 315 years) whom an investigator prescribes the first gabapentin (tablets, syrup, and switch to syrup from tablet) should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random. Patients who have been enrolled in the drug use investigation of Gabapen tablets in adults (protocol No. A9451163). Patients who receive Gabapen tablets or syrup before, except for switched from tablets to syrup.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gabapentin</keyword>
	<keyword>Epilepsies</keyword>
	<keyword>safety</keyword>
</DOC>